The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks

ISBN-13: 9781009009898 / Angielski / Miękka / 2021 / 256 str.

Jonathan M. Meyer; Stephen M. Stahl

Opis

A comprehensive and accessible guide to using antipsychotic levels for optimizing effectiveness and monitoring oral antipsychotic adherence.

Recenzje

'Drs. Jonathan Meyer and Stephen M. Stahl provide a comprehensive review of the state of the knowledge on the use of antipsychotic plasma levels for the management of patients with schizophrenia, as well as useful practical information for practicing clinicians. The handbook is written and organized in a manner that facilitates the learning of new concepts and its use as a reference tool. It should be an invaluable resource for clinicians facing the frequent scenario of patients exhibiting poor response or poor tolerance to the prescribed antipsychotic drug. It is to be hoped that this handbook and other dissemination efforts expand the use of therapeutic drug monitoring of antipsychotic treatment.' Marcela Horvitz-Lennon, Senior Physician Scientist, RAND Corporation; Associate Professor, Cambridge Health Alliance and Harvard Medical School

Spis treści

Preface; Introduction; 1. Sampling times for oral and long-acting injectable agents; 2. The therapeutic threshold and the point of futility; 3. Level interpretation including laboratory reporting issues, responding to high plasma levels, special situations (hepatic dysfunction, renal dysfunction and hemodialysis, bariatric surgery); 4. Tracking oral antipsychotic adherence; 5. What is an adequate antipsychotic trial – using plasma levels to optimize psychiatric response and tolerability; 6. Important concepts about first generation antipsychotics; 7. Haloperidol and haloperidol decanoate; 8. Fluphenazine and fluphenazine decanoate; 9. Perphenazine and perphenazine decanoate; 10. Zuclopenthixol and zuclopenthixol decanoate; flupenthixol and flupenthixol decanoate; 11. Chlorpromazine, loxapine, thiothixene, trifluoperazine; 12. Important concepts about second generation antipsychotics; 13. Clozapine; 14. Risperidone oral and long-acting injectable, paliperidone oral and long-acting injectable; 15. Olanzapine and olanzapine pamoate; 16. Aripiprazole, aripiprazole monohydrate and aripiprazole lauroxil; 17. Amisulpride, asenapine, lurasidone, brexpiprazole, cariprazine; Appendix Therapeutic threshold, point of futility, AGNP/ASCP laboratory alert level, and average oral concentration-dose relationships.